Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Flolan on inhibition of platelet ADP receptor in healthy volunteers
2007-003816-77Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Aug 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of epoprostenol in normal platelet function, sponsored by Rigshospitalet. Primary endpoint: Platelet ADP receptor inhibition measured by TEG Platelet Mapping Assay. Started Aug 2008; status: completed.
02
Drugs
epoprostenol
03
Conditions
normal platelet function
Beyond the preview
Go deeper on 2007-003816-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003816-77.